Study Details

Back to Search Results

ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects with Metastatic Urothelial Cancer

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT01963052

Astellas Study ID

The unique identification code given by the study sponsor.

AGS15E-13-1

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Bladder Cancer

Phase

These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1

Age

18 years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Nov 2013 - Jul 2019

Masking

None (Open Label)

Enrollment number

93

A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS15E Given as Monotherapy in Subjects with Metastatic Urothelial Cancer

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects with Metastatic Urothelial Cancer? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site CA00004

Vancouver, Canada, V5Z 1H5

Site US00002

New Haven, United States, 06510

Site US00012

New York, United States, 10029

Site CA00007

Hamilton, Canada, L8V 5C2

Site CA00005

Toronto, Canada, M4N 3M5

Site US00003

St. Louis, United States, 63110

Site US00001

Detroit, United States, 48201

Site US00009

Buffalo, United States, 14263

Site US00008

Seattle, United States, 98109

Site US00010

Nashville, United States, 37212

Site US00011

Pittsburgh, United States, 15232

Site US00006

Birmingham, United States, 35294

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo